Helsinn Group grants rights Gen ILAC for Turkey -
The exclusive distribution and licensing agreement for the commercialization of Helsinn currently has in development for the anorexia- treatment of cachexia syndrome cancer in non-small lung cancer (NSCLC) patients
Helsinn Group, the company focused on strengthening quality care against cancer, today announces the rights to Anamorelin, its receptor agonist innovative ghrelin, have been granted to Turkey for Ilaç GEN.
Anamorelin is a novel pioneering oral drug, once daily in development for the treatment of cancer anorexia-cachexia syndrome ( "CACS"). The current phase III studies are designed to evaluate the safety and efficacy in increasing body weight, lean body mass, muscle strength, and patient quality of life. The main objective of the studies is non-small lung cancer and is almost complete.
Under the terms of the agreement, Helsinn will retain all development activities (chemistry, manufacturing and controls, preclinical and clinical) and supply of Anamorelin for commercial use. GEN Ilaç will be responsible for regulatory approval and commercial activities in their territories
Riccardo Braglia, CEO of Helsinn group, said :. "We are excited to take our first important step towards Turkey Anamorelin with a company with the reputation and reach of GEN Ilaç. Drugs like Anamorelin, targeting important therapeutic areas of unmet need such as CACS, will help improve the quality of life of patients living with cancer and help us achieve our goal of becoming the world leader in cancer supportive care company "
Gülmüs Abidin, CEO of GEN Ilaç added:" We are .. proud of our reputation as a leading specialty pharmaceutical companies in Turkey and we are delighted to have a successful partnership with Helsinn We look forward to providing Anamorelin oncologists for the treatment of patients with CACS. "
EmoticonEmoticon